- Home
- CMMB vs CANF Comparison
CMMB vs CANF Comparison
Compare CMMB & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- CANF
- Stock Information
- Founded
- CMMB 2004
- CANF 1994
- Country
- CMMB Israel
- CANF Israel
- Employees
- CMMB N/A
- CANF N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- CMMB Health Care
- CANF Health Care
- Exchange
- CMMB Nasdaq
- CANF Nasdaq
- Market Cap
- CMMB 15.8M
- CANF 14.4M
- IPO Year
- CMMB N/A
- CANF N/A
- Fundamental
- Price
- CMMB $1.43
- CANF $2.00
- Analyst Decision
- CMMB Strong Buy
- CANF Strong Buy
- Analyst Count
- CMMB 3
- CANF 2
- Target Price
- CMMB $5.67
- CANF $14.00
- AVG Volume (30 Days)
- CMMB 203.8K
- CANF 111.6K
- Earning Date
- CMMB 11-07-2024
- CANF 11-15-2024
- Dividend Yield
- CMMB N/A
- CANF N/A
- EPS Growth
- CMMB N/A
- CANF N/A
- EPS
- CMMB N/A
- CANF N/A
- Revenue
- CMMB N/A
- CANF $667,000.00
- Revenue This Year
- CMMB N/A
- CANF $356.93
- Revenue Next Year
- CMMB N/A
- CANF N/A
- P/E Ratio
- CMMB N/A
- CANF N/A
- Revenue Growth
- CMMB N/A
- CANF N/A
- 52 Week Low
- CMMB $0.42
- CANF $1.81
- 52 Week High
- CMMB $2.55
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- CMMB 39.25
- CANF 38.27
- Support Level
- CMMB $1.29
- CANF $1.87
- Resistance Level
- CMMB $1.58
- CANF $2.04
- Average True Range (ATR)
- CMMB 0.16
- CANF 0.14
- MACD
- CMMB -0.04
- CANF 0.01
- Stochastic Oscillator
- CMMB 24.11
- CANF 38.24
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).